Clinical Study to Evaluate Efficacy of New Paracetamol Formulation Compared to Ibuprofen in Headache
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01842633 |
Recruitment Status :
Terminated
First Posted : April 29, 2013
Results First Posted : July 27, 2017
Last Update Posted : September 1, 2017
|
Sponsor:
GlaxoSmithKline
Information provided by (Responsible Party):
GlaxoSmithKline
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Double (Participant, Investigator); Primary Purpose: Treatment |
Condition |
Pain |
Interventions |
Drug: Paracetamol and Caffeine Drug: Ibuprofen Other: Placebo |
Enrollment | 365 |
Participant Flow
Recruitment Details | Participants were recruited at clinical sites in the United States. |
Pre-assignment Details | 365 participants were enrolled in the study out of which 165 participants were randomized in the study. 200 participants were not randomized for the following reasons: 165 were screening failure, 3 due to Adverse Events (AEs), 7 were lost to follow-up, 19 withdrawals by participant, and 6 due to other reasons. |
Arm/Group Title | Paracetamol/ Caffeine Caplets | Ibuprofen Caplets | Placebo Caplets |
---|---|---|---|
Arm/Group Description | Participants were administered with two caplets of paracetamol/caffeine combination 500/65milligram (mg) plus 2 placebo caplets orally with 8 ounces of water | Participants were administered with two caplets of ibuprofen 200mg plus 2 placebo caplets orally with 8 ounces of water | Participants were administered with four placebo caplets with 8 ounces of water |
Period Title: Overall Study | |||
Started | 65 | 66 | 34 |
Completed | 62 | 64 | 34 |
Not Completed | 3 | 2 | 0 |
Reason Not Completed | |||
Screen Failure | 1 | 0 | 0 |
Adverse Event | 1 | 1 | 0 |
Withdrawal by Subject | 0 | 1 | 0 |
Technical issues | 1 | 0 | 0 |
Baseline Characteristics
Arm/Group Title | Paracetamol/ Caffeine Caplets | Ibuprofen Caplets | Placebo Caplets | Total | |
---|---|---|---|---|---|
Arm/Group Description | Participants were administered with two caplets of paracetamol/caffeine combination 500/65mg plus 2 placebo caplets orally with 8 ounces of water | Participants were administered with two caplets of ibuprofen 200mg plus 2 placebo caplets orally with 8 ounces of water | Participants were administered with four placebo caplets orally with 8 ounces of water | Total of all reporting groups | |
Overall Number of Baseline Participants | 62 | 62 | 33 | 157 | |
Baseline Analysis Population Description |
Demography data is available for 157 Participants only (safety Population).
|
||||
Age, Continuous
Mean (Standard Deviation) Unit of measure: Years |
|||||
Number Analyzed | 62 participants | 62 participants | 33 participants | 157 participants | |
39.9 (11.39) | 38.1 (13.13) | 38.5 (12.65) | 38.9 (12.32) | ||
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
|||||
Number Analyzed | 62 participants | 62 participants | 33 participants | 157 participants | |
Female |
46 74.2%
|
44 71.0%
|
23 69.7%
|
113 72.0%
|
|
Male |
16 25.8%
|
18 29.0%
|
10 30.3%
|
44 28.0%
|
|
Race (NIH/OMB)
Measure Type: Count of Participants Unit of measure: Participants |
|||||
Number Analyzed | 62 participants | 62 participants | 33 participants | 157 participants | |
American Indian or Alaska Native |
0 0.0%
|
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Asian |
1 1.6%
|
0 0.0%
|
1 3.0%
|
2 1.3%
|
|
Native Hawaiian or Other Pacific Islander |
0 0.0%
|
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Black or African American |
4 6.5%
|
6 9.7%
|
4 12.1%
|
14 8.9%
|
|
White |
56 90.3%
|
55 88.7%
|
28 84.8%
|
139 88.5%
|
|
More than one race |
1 1.6%
|
1 1.6%
|
0 0.0%
|
2 1.3%
|
|
Unknown or Not Reported |
0 0.0%
|
0 0.0%
|
0 0.0%
|
0 0.0%
|
Outcome Measures
Adverse Events
Limitations and Caveats
Enrollment into the trial was terminated after randomization of 62% of the plan resulting in a significant reduction in study power. The originally planned inferential statistics (p-values) were therefore not presented in tables summarizing results.
More Information
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts
the PI's rights to discuss or publish trial results after the trial is completed.
GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
Results Point of Contact
Name/Title: | GSK Response Center |
Organization: | GlaxoSmithKline |
Phone: | 866-435-7343 |
Responsible Party: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT01842633 |
Other Study ID Numbers: |
202172 RH01649 ( Other Identifier: GSK ) |
First Submitted: | April 25, 2013 |
First Posted: | April 29, 2013 |
Results First Submitted: | June 2, 2016 |
Results First Posted: | July 27, 2017 |
Last Update Posted: | September 1, 2017 |